As optimism for GLP-1 receptor agonists for weight loss has grown, so too has their use in children. Currently, liraglutide ...

Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong ...

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

This intrusive, but common phenomenon can take over your life, affecting your state of mind and eating habits. Weight-loss drugs show promise in quieting these thoughts.

The system is expected to strengthen into a tropical storm by the end of the day and continue strengthening if it remains ...

From there, the case for or against investing in Lilly should become much clearer. Eli Lilly's earnings report ...

The following chart lists examples of mild side effects ... the American Diabetes Association’s treatment guidelines recommend GLP-1 agonists (the drug class Ozempic and Victoza belong to ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

Glucagon-like peptide-1 receptor (GLP-1) agonists, particularly semaglutide, could be effective in reducing alcohol-related hospitalisations. Read more!

Coya Therapeutics (COYA) releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan….”Given my recent ...